Given that RIPK4 has been shown to play a role in the activation of the NF-κB pathway, and its expression negatively correlates with the predicted presence of T cells in human ovarian cancer [22, 33], we reasoned that RIPK4 may be modulating the tumor microenvironment. The gene discussed is NFKB1; the disease is ovarian carcinoma.